![](/images/graphics-bg.png)
Botulinum toxin type a therapy in migraine : preclinical and clinical trials
Joint Authors
Zhang, Yi
Shao, Yu-Feng
Zhao, Peng
Yan, Wen-Jun
Kong, Xiang-Pan
Fan, Lin-Lan
Hou, Yi-Ping
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 15, Issue 10 (31 Oct. 2013), pp.1-8, 8 p.
Publisher
Publication Date
2013-10-31
Country of Publication
United Arab Emirates
No. of Pages
8
Main Subjects
Topics
Abstract AR
Introduction: Botulinum toxin type A (BTX-A) has been reported to be effective for the therapy for migraine.
The purpose of this study was to investigate the effect of BTX-A on the immunoreactive levels of calcitonin gene-related peptide (CGRP) and substance P (SP) in the jugular plasma and medulla oblongata of migraine in rats induced by nitroglycerin (NTG), and then to evaluate and compare the effectiveness of fixed (muscle)-sites and acupoint-sites injection of BTX-A for migraine therapy of patients in a randomly controlled trial extending over four months.
Materials and Methods: Rats with NTG-induced migraine were subcutaneously injected with vehicle or BTX-A (5 U/kg or 10 U/kg bodyweight).
CGRP- and SP-like immunoreactivity (CGRP-LI and SP-LI) were determined by radioimmunoassay.
In clinical trials, sixty patients respectively received BTX-A (2.5 U each site, 25 U per patient) at fixed-sites (group F, n = 30) including occipitofrontalis, corrugator supercili, temporalis and trapezius or at acupoint-sites (group A, n = 30) including EX-HN3, EX-HN5, GV20, GB8, GB20 and BL10.
Results: Local BTX-A injection suppressed NTG-induced CGRP-LI and SP-LI levels in jugular plasma and oblongata.
BTX-A injection for both groups with migraine significantly reduced the attack frequency, intensity, duration and associated symptoms.
The efficacy of BTX-A for migraine in group A (93% improvement) was more significant than that in group F (83% improvement) (P < 0.01).
Conclusions: The evidence that BTX-A decreases NTG-induced CGRP-LI and SP-LI levels in trigeminovascular system suggests that BTX-A attenuates migraine by suppression of neuropeptide release.
BTX-A injections for migraine at acupoint-sites and fixed-sites are effective.
Acupoint-sites BTX-A administration shows more efficacy for migraine than fixed-sites application.
Abstract EN
Introduction : Botulinum toxin type A (BTX-A) has been reported to be effective for the therapy for migraine.
The purpose of this study was to investigate the effect of BTX-A on the immunoreactive levels of calcitonin gene-related peptide (CGRP) and substance P (SP) in the jugular plasma and medulla oblongata of migraine in rats induced by nitroglycerin (NTG), and then to evaluate and compare the effectiveness of fixed (muscle)-sites and acupoint-sites injection of BTX-A for migraine therapy of patients in a randomly controlled trial extending over four months.
Materials and Methods : Rats with NTG-induced migraine were subcutaneously injected with vehicle or BTX-A (5 U / kg or 10 U / kg bodyweight).
CGRP- and SP-like immunoreactivity (CGRP-LI and SP-LI) were determined by radioimmunoassay.
In clinical trials, sixty patients respectively received BTX-A (2.5 U each site, 25 U per patient) at fixed-sites (group F, n = 30) including occipitofrontalis, corrugator supercili, temporalis and trapezius or at acupoint-sites (group A, n = 30) including EX-HN3, EX-HN5, GV20, GB8, GB20 and BL10.
Results : Local BTX-A injection suppressed NTG-induced CGRP-LI and SP-LI levels in jugular plasma and oblongata.
BTX-A injection for both groups with migraine significantly reduced the attack frequency, intensity, duration and associated symptoms.
The efficacy of BTX-A for migraine in group A (93 % improvement) was more significant than that in group F (83 % improvement) (P < 0.01).
Conclusions : The evidence that BTX-A decreases NTG-induced CGRP-LI and SP-LI levels in trigeminovascular system suggests that BTX-A attenuates migraine by suppression of neuropeptide release.
BTX-A injections for migraine at acupoint-sites and fixed-sites are effective.
Acupoint-sites BTX-A administration shows more efficacy for migraine than fixed-sites application.
American Psychological Association (APA)
Shao, Yu-Feng& Zhang, Yi& Zhao, Peng& Yan, Wen-Jun& Kong, Xiang-Pan& Fan, Lin-Lan…[et al.]. 2013. Botulinum toxin type a therapy in migraine : preclinical and clinical trials. Iranian Red Crescent Medical Journal،Vol. 15, no. 10, pp.1-8.
https://search.emarefa.net/detail/BIM-340644
Modern Language Association (MLA)
Zhao, Peng…[et al.]. Botulinum toxin type a therapy in migraine : preclinical and clinical trials. Iranian Red Crescent Medical Journal Vol. 15, no. 10 (Oct. 2013), pp.1-8.
https://search.emarefa.net/detail/BIM-340644
American Medical Association (AMA)
Shao, Yu-Feng& Zhang, Yi& Zhao, Peng& Yan, Wen-Jun& Kong, Xiang-Pan& Fan, Lin-Lan…[et al.]. Botulinum toxin type a therapy in migraine : preclinical and clinical trials. Iranian Red Crescent Medical Journal. 2013. Vol. 15, no. 10, pp.1-8.
https://search.emarefa.net/detail/BIM-340644
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 7-8
Record ID
BIM-340644